Metis Techbio-p (07666.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 16.34B

MomentumView details →

1D Return

+5.02%

YTD Return

—

RSI (14)

55.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 16.34B

RSI (14)

55.1

MomentumView details →

1D Return

+5.02%

YTD Return

—

ProfitabilityView details →

Gross Margin

66.01%

Net Margin

−373.18%

EBITDA Margin

−310.36%

ROE (TTM)

−36.66%

ROA (TTM)

−29.57%

Asset Turnover

0.08x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+232.78%

EPS CAGR 3Y

+21.96%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

4514.89%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

6.67x

Quick Ratio

6.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 3, 2027 →

Latest newsMore news →

Biotech company Metis Therapeutics (07666.HK) has leased space in the Central YING KING Building managed by real estate asset management firm Three Capitals, which announced the tenancy.16d ago

Similar companies

Jazz Pharmaceuticals plcJAZZ 神州细胞688520.SH Xcell Therapeutics, Inc.373110.KQ Ascendis Pharma A/SASND Exelixis, Inc.EXEL BridgeBio Pharma, Inc.BBIO Find similar companies →

Latest newsMore news →

Biotech company Metis Therapeutics (07666.HK) has leased space in the Central YING KING Building managed by real estate asset management firm Three Capitals, which announced the tenancy.16d ago